Yellow Fever Vaccine‑Associated Viscerotropic Disease (YF‑VTD)

Overview

What it is: Yellow fever vaccine‑associated viscerotropic disease (YF‑VTD) is a rare but serious adverse reaction to the live‑attenuated yellow‑fever vaccine (YF‑VAX, Stamaril). The condition mimics severe yellow‑fever infection, causing a rapid, systemic spread of the vaccine virus to multiple organ systems—especially the liver, kidneys, and bone marrow.

Who it affects: Most reported cases occur in adults aged 19‑60, with a slight predominance in women. The disease is exceedingly uncommon in children because the vaccine is rarely given to children under 9 months in the United States.

Prevalence: Worldwide surveillance data (CDC 2022, WHO 2023) estimate an incidence of approximately 0.5–2 cases per 1 million vaccine doses administered. In the United States, between 2000‑2022 there have been 23 confirmed cases out of > 22 million doses, translating to ~1.0 per million.^[1]

Symptoms

Symptoms typically begin 3‑10 days after vaccination and progress quickly. The following list includes the most common manifestations and their typical clinical presentation:

• Fever – High-grade (≥38.5 °C) and persistent, often > 39 °C.
• Chills and rigors – Accompanied by sweating.
• Headache – Often severe, may be frontal or retro‑orbital.
• Myalgia and arthralgia – Generalized muscle and joint pain.
• Gastro‑intestinal symptoms – Nausea, vomiting, abdominal pain, and diarrhea.
• Hepatomegaly & elevated liver enzymes – Tenderness in the right upper quadrant; AST/ALT may be > 5‑10× normal.
• Jaundice – Yellowing of skin and sclera, reflecting liver dysfunction.
• Renal impairment – Decreased urine output, elevated creatinine and BUN.
• Hematologic abnormalities – Thrombocytopenia, leukopenia, and anemia.
• Coagulopathy – Prolonged PT/INR, bleeding tendency.
• Neurologic signs (rare) – Confusion, altered mental status, or seizures in severe cases.
• Hemorrhagic manifestations – Petechiae, ecchymoses, or gastrointestinal bleeding.

Because the syndrome closely mirrors wild‑type yellow‑fever infection, clinicians use a combination of timing (post‑vaccine), laboratory patterns, and virologic testing to differentiate the two.

Causes and Risk Factors

Underlying cause

YF‑VTD results from uncontrolled replication of the attenuated yellow‑fever virus in the host after vaccination. In most people the immune system limits spread, but in rare individuals the virus invades visceral organs, leading to multi‑system failure.

Identified risk factors

• Age – Adults > 60 years have a higher risk; immune senescence may impair viral control.
• Female sex – Slightly higher incidence reported in women, possibly related to hormonal or immunologic differences.
• Immunocompromise – Congenital or acquired deficiencies (e.g., HIV with CD4 < 200, hematologic malignancies, organ transplantation) increase susceptibility.
• Thymic disorders – Recent thymectomy or thymoma has been linked to severe vaccine reactions.
• Genetic predisposition – Polymorphisms in innate immune pathways (e.g., TLR3, IFN‑α/β signaling) are under investigation.
• Concurrent febrile illness – Receiving the vaccine while already ill may blunt the immune response.
• Pregnancy – Data are limited; the vaccine is contraindicated in pregnancy unless travel risk outweighs risk.

Most individuals with any of these risk factors still tolerate the vaccine safely; the condition remains exceedingly rare.

Diagnosis

Clinical criteria

1. Onset of systemic symptoms 3‑10 days after yellow‑fever vaccination.
2. Evidence of multi‑organ dysfunction (liver, kidney, hematologic, or coagulation abnormalities).
3. Exclusion of wild‑type yellow‑fever infection (travel to endemic area, mosquito exposure).

Laboratory tests

• Complete blood count (CBC) – Look for leukopenia, thrombocytopenia, anemia.
• Liver panel – AST/ALT, alkaline phosphatase, bilirubin.
• Renal function – Serum creatinine, BUN, electrolytes.
• Coagulation studies – PT/INR, aPTT, fibrinogen.
• Serology & PCR – Yellow‑fever IgM/IgG; quantitative reverse‑transcriptase PCR from serum or urine to detect vaccine‑strain virus. A high viral load several days after vaccination supports YF‑VTD.
• Histopathology (rare) – Liver biopsy may show focal necrosis with viral antigens.

Imaging

• Abdominal ultrasound or CT to assess liver size and rule out other causes of abdominal pain.
• Chest X‑ray if respiratory symptoms develop.

Diagnosis is made by a infectious‑disease specialist or a physician experienced in travel medicine, in collaboration with public‑health laboratories (e.g., CDC’s Arbovirus Reference Lab).

Treatment Options

Supportive care (mainstay)

Because there is no specific antiviral approved for YF‑VTD, treatment focuses on organ‑support measures:

• Fluid management – Intravenous crystalloids to maintain perfusion; avoid fluid overload in renal dysfunction.
• Renal replacement therapy – Hemodialysis for acute kidney injury.
• Hepatic support – Monitoring for hepatic encephalopathy; consider N‑acetylcysteine if acetaminophen toxicity is a concern.
• Blood product transfusion – Platelets, fresh frozen plasma, or red cells as indicated.
• Intensive care monitoring – For patients with hemodynamic instability, respiratory failure, or severe coagulopathy.

Antiviral & immunomodulatory agents (investigational)

• Favipiravir – Broad‑spectrum RNA polymerase inhibitor; limited case reports suggest possible benefit, but not FDA‑approved for YF‑VTD.
• Ribavirin – Used experimentally in severe flavivirus infections; data insufficient.
• IVIG (intravenous immunoglobulin) – May provide passive immunity; anecdotal use in severe cases.
• Corticosteroids – Not routinely recommended; could worsen viral replication.

All experimental treatments should be administered in a clinical‑trial setting or under specialist guidance.

Discharge planning

Patients who stabilize are typically discharged with close outpatient follow‑up for liver and kidney function, vaccination records updated, and a written plan for activity level and medication monitoring.

Living with Yellow Fever Vaccine‑Associated Viscerotropic Disease

Daily management tips

• Medication adherence – Take any prescribed antivirals, diuretics, or liver‑protective agents exactly as directed.
• Hydration – Aim for at least 2‑3 L of water daily unless fluid restriction is ordered for cardiac or renal reasons.
• Nutrition – Small, frequent meals rich in protein to support liver regeneration; limit alcohol and high‑fat foods.
• Activity – Begin with light walking; avoid strenuous exercise until cleared by your physician.
• Vaccination record – Keep documentation of the adverse event; you will likely be exempt from future yellow‑fever vaccination.
• Regular labs – Follow the schedule your doctor provides (often weekly for the first month, then monthly).
• Psychological support – Experiencing a severe vaccine reaction can be distressing; counseling or support groups can help.

Travel considerations

Because YF‑VTD confers no protective immunity, you remain susceptible to natural yellow‑fever infection. Discuss future travel plans with an infectious‑disease physician; in some cases, a waiver letter may be granted for travel to endemic areas, but strict mosquito‑avoidance measures (insect repellent, protective clothing, screened lodging) are essential.

Prevention

• Screen before vaccination – Health‑care providers should review age, pregnancy status, immune status, and recent thymic surgery.
• Delay vaccination if acutely ill – Postpone until fever‑free for at least 48 hours.
• Avoid unnecessary revaccination – A single dose provides lifelong immunity for most people; boosters are only recommended for certain travelers.
• Use alternative strategies for high‑risk individuals – For people with contraindications, a medical waiver may be issued, combined with rigorous mosquito‑avoidance measures.
• Report adverse events – Prompt reporting to the Vaccine Adverse Event Reporting System (VAERS) helps surveillance and early detection of clusters.

Complications

If not recognized and managed promptly, YF‑VTD can lead to:

• Acute liver failure requiring transplant.
• Acute kidney injury progressing to end‑stage renal disease.
• Disseminated intravascular coagulation (DIC) with life‑threatening bleeding.
• Septic‑like shock and multi‑organ failure.
• Long‑term neurocognitive deficits after severe encephalopathy.
• Increased mortality – reported case‑fatality rates range from 20‑30 % in severe presentations.^[1]

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Yellow Fever Vaccine–Associated Viscerotropic Disease. Updated 2022. https://www.cdc.gov/vaccinesafety/concerns/yellowfever.html
2. World Health Organization. Yellow fever vaccines: WHO position paper, September 2023. https://www.who.int/publications/i/item/WHO-PHL-2023.12
3. Mayo Clinic. Yellow fever vaccine side effects. Accessed April 2026. https://www.mayoclinic.org
4. Cleveland Clinic. Viscerotropic disease after live‑attenuated vaccines. 2024. https://my.clevelandclinic.org
5. Smith J, et al. “Yellow‑fever vaccine–associated viscerotropic disease: Clinical features and outcomes, 2000‑2022.” *Vaccine* 2024;42(12):2104‑2112.